ARTICLE | Emerging Company Profile
Accession: precisely targeted oncolytic viruses
Bent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism
November 21, 2022 1:00 PM UTC
With an engineering technique that targets oncolytic viruses to specific tumor antigens, Accession is aiming for more precise killing of targeted cancer cells — and those immediately surrounding them — while avoiding off-target effects.
Co-founded by Bent Jakobsen, who also founded Adaptimmune Therapeutics plc (NASDAQ:ADAP) and Immunocore Holdings plc (NASDAQ:IMCR), Accession Therapeutics Ltd. has topped off an £11 million ($12.6 million) seed financing with a £16.6 million round from investors including iGlobe Partners, Primavera Venture Partners and Birk Venture...